Figure 3.
RPARP-AS1 sponged miR-125a-5p. (A) RPARP-AS1 was mainly expressed in nucleus, but not in cytoplasm (U6 and GAPDH were used as internal parameters of nucleus and cytoplasm respectively). (B) The binding site of miR-125a-5p was found in RPARP-AS1 by analyzing the startbase3 database. (C) RNA pull-down assay was performed in HT29 and HCT116 cells. miR-125a-5p probe enriched more RPARP-AS1 than NC probe (Left). Luciferase reporter experiment showed that miR-125a-5p could inhibit the activity of luciferase coupling with RPARP-AS1, but miR-NC could not in both HCT116 (Middle) and LoVo (Right) cell lines. (D) qRT-PCR was used to detect the expression of mir-125a-5p after knockdown of RPARP-AS1 in HT29 and HCT116 cells. Compared with si-NC groups, miR-125a-5p expression increased in si-RPARP-AS1 cell lines. (E) miR-125a-5p expression decreased significantly in CRC than that in paracarcinomatic tissue by qRT-PCR (n=30, P-value<0.001). (F) Consistent with those in Figure E, miR-125a-5p reduced in CRC significantly using data from TCGA by Startbase3 analysis. (G) The correlation between the expression of RPARP-AS1 and miR-125a-5p in 30 cases of CRC which was negatively correlated (P-value<0.001). (H) The expression of RPARP-AS1 and miR-125a-5p in CRC was also negatively correlated using data from TCGA by Startbase3 analysis. (**P-value < 0.01; ***P-value < 0.001).